Neoadjuvant therapy
Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients
Publication: Miami Breast Authors Pat Whitworth, James Read More
MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer
PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Read More
Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Jr., Read More
5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Read More
I-SPY2: Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
I-SPY2, JAMA Oncology, 2020 Authors: Yee et al.
Read More
ASCO 2020: Chemokine Signature
PUBLICATION: ASCO 20 AUTHORS: Hatem Soliman, Sangeetha Prabhakaran, Marilin Rosa, Read More
ASCO June 5 2019: Race and response to neoadjuvant chemotherapy
AUTHORS: Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Read More
NBRST: ER-positive basal-type breast cancers, respond like TNBC
NPJ Breast Cancer, April 2019 Author: Groenendijk et al.
Read More
Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers
PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). Read More
BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2
AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Read More
